Literature DB >> 27694685

Expanded HTA, Legitimacy and Independence Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".

Keith Syrett1.   

Abstract

This brief commentary seeks to develop the analysis of Daniels, Porteny and Urrutia of the implications of expansion of the scope of health technology assessment (HTA) beyond issues of safety, efficacy, and cost-effectiveness. Drawing in particular on experience in the United Kingdom, it suggests that such expansion can be understood not only as a response to the problem of insufficiency of evidence, but also to that of legitimacy. However, as expansion of HTA also renders it more visibly political in character, it is plausible that its legitimacy may be undermined, rather than enhanced by, independence from the policy process.
© 2016 by Kerman University of Medical Sciences.

Entities:  

Keywords:  Budget Impact; Equity; Health Technology Assessment (HTA); Independence; Legitimacy; Regulation; Threshold

Mesh:

Year:  2016        PMID: 27694685      PMCID: PMC5010661          DOI: 10.15171/ijhpm.2016.75

Source DB:  PubMed          Journal:  Int J Health Policy Manag        ISSN: 2322-5939


  13 in total

Review 1.  The politics of evidence-based medicine.

Authors:  M A Rodwin
Journal:  J Health Polit Policy Law       Date:  2001-04       Impact factor: 2.265

2.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

3.  NICE's social value judgements about equity in health and health care.

Authors:  Koonal K Shah; Richard Cookson; Anthony J Culyer; Peter Littlejohns
Journal:  Health Econ Policy Law       Date:  2012-05-01

4.  Pharmacoeconomics: NICE's approach to decision-making.

Authors:  Michael Rawlins; David Barnett; Andrew Stevens
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

5.  Expanded HTA: Enhancing Fairness and Legitimacy.

Authors:  Norman Daniels; Thalia Porteny; Julian Urritia
Journal:  Int J Health Policy Manag       Date:  2015-11-06

6.  Pharmacopolitics and deliberative democracy.

Authors:  Michael D Rawlins
Journal:  Clin Med (Lond)       Date:  2005 Sep-Oct       Impact factor: 2.659

7.  Ethics and opportunity costs: have NICE grasped the ethics of priority setting?

Authors:  J McMillan; M Sheehan; D Austin; J Howell
Journal:  J Med Ethics       Date:  2006-03       Impact factor: 2.903

8.  [Health policy decisions between rationing and rationalization--exemplified by erythropoietin in tumor anemia].

Authors:  C Wild; S Jonas
Journal:  Gesundheitswesen       Date:  2001-04

9.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Authors:  Karl Claxton; Steve Martin; Marta Soares; Nigel Rice; Eldon Spackman; Sebastian Hinde; Nancy Devlin; Peter C Smith; Mark Sculpher
Journal:  Health Technol Assess       Date:  2015-02       Impact factor: 4.014

10.  Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.

Authors:  Anthony Culyer; Christopher McCabe; Andrew Briggs; Karl Claxton; Martin Buxton; Ron Akehurst; Mark Sculpher; John Brazier
Journal:  J Health Serv Res Policy       Date:  2007-01
View more
  1 in total

1.  Ethics in HTA: Examining the "Need for Expansion".

Authors:  Payam Abrishami; Wija Oortwijn; Bjørn Hofmann
Journal:  Int J Health Policy Manag       Date:  2017-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.